FDA Approves Spineart's BAGUERA® C Cervical Disc for 1 and 2 Contiguous Levels

Spineart has announced that its BAGUERA® C cervical disc has received FDA approval for use at one and two contiguous levels. This approval expands access in the United States to a motion-preserving solution for patients suffering from cervical disc disease. The device has nearly two decades of international clinical experience, with over 80,000 devices sold worldwide, and the FDA approval is supported by two randomized controlled trials involving almost 600 U.S. patients.